Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)

Douglas W. Blayney, MD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2019) 134 (Supplement_1): 3590.

https://doi.org/10.1182/blood-2019-127310

Published: 2019

Journal Articles

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Ramon Mohanlal, PhD MD, Douglas W. Blayney, MD, Lan Huang, PhD

Blood (2019) 134 (Supplement_1): 4860.

https://doi.org/10.1182/blood-2019-128563

Published: 2019

Journal Articles

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Douglas W. Blayney, MD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2019) 134 (Supplement_1): 4861.

https://doi.org/10.1182/blood-2019-127227

Published: 2019

Journal Articles

Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

Douglas W. Blayney, MD, Ene Ette, PhD, Stephan Ogenstad, PhD, Yuankai Shi, MD PhD, Lihua Du, Kenneth Lloyd, PhD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2018) 132 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2018-99-113569

Published: 2018

Journal Articles

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Vittorio Ruggero Zilioli, Periana Minga, Lara Crucitti, Erika Meli, Monica Luigia Torretta, Anna Esposito, Chiara Rusconi, Roberto Cairoli

Blood (2018) 132 (Supplement 1): 5374.

https://doi.org/10.1182/blood-2018-99-116543

Published: 2018

Journal Articles

Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy

Douglas W Blayney, MD, Lyudmila Bazhenova, MD, G. Kenneth Lloyd, PhD, Lan Huang, PhD, Ramon Mohanlal, MD PhD

Blood (2016) 128 (22): 2508.

https://doi.org/10.1182/blood.V128.22.2508.2508

Published: 2016

Journal Articles

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)

Preetesh Jain, MBBS,MDDM,PhD, Keyur P. Patel, MD PhD, Andrew Futreal, PhD, Curtis Gumbs, Shimin Hu, PhD MD, Carlos Bueso Ramos, MD, Michael Wang, MD, Jorge Romaguera, Luis E. Fayad, MD, Robert Z. Orlowski, PhD, MD, Jeffrey Medeiros, Nathan Fowler, MD

Blood (2015) 126 (23): 2700.

https://doi.org/10.1182/blood.V126.23.2700.2700

Published: 2015

Journal Articles

Proposed Biosimilar Pegfilgrastim (LA-EP2006) and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients with Breast Cancer: A Randomized, Double-Blind Trial. Protect 2: Pegfilgrastim Randomized Oncology (supportive care) Trial to Evaluate Comparative Treatment Results

Kimberley Blackwell, Ruslan Paltuev, Roman Donskih, Olga Burdaeva, Elena Bit-Sava, Tanveer Maksud, Michael Jones, Allen Nixon, Maria J Vidal, Roumen Nakov, Pritba Singh, Gregor Schaffer, Pere Gascon, Nadia Harbeck

Blood (2015) 126 (23): 632.

https://doi.org/10.1182/blood.V126.23.632.632

Published: 2015

Journal Articles

Phase Ib Studies of Benegrastim in Chinese Women with Breast Cancer Receiving Myelotoxic Chemotherapy

Junning Cao, MD, Zhongyu Yuan, MD, Cheng Huang, MD, Dongmei Ji, MD, Rujun Peng, MD, Xiaoqiang Yan, PhD, Tom Tang, MD

Blood (2015) 126 (23): 4601.

https://doi.org/10.1182/blood.V126.23.4601.4601

Published: 2015

Journal Articles

Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens

Leila Family, PhD, Su-Jau Yang, Zandra Klippel, MD, Yanli Li, MD PhD, John H Page, MD ScD, Roberto Rodriguez, MD, Chun Chao, PhD

Blood (2015) 126 (23): 3257.

https://doi.org/10.1182/blood.V126.23.3257.3257

Published: 2015

Journal Articles

The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program

Giuseppe Saglio, MD, Philipp le Coutre, MD, Jorge E. Cortes, MD, Jiří Mayer, MD, Philip A. Rowlings, MBBS FRACP FRCPA MS, Francois-Xavier Mahon, MD PhD, Glenn S. Kroog, MD, Kyna Gooden, PhD MPH, Milayna Subar, MD, Jeanette A. Preston, MD MPH, Neil P. Shah, MD PhD

Blood (2014) 124 (21): 4534.

https://doi.org/10.1182/blood.V124.21.4534.4534

Published: 2014

Journal Articles

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Chul S. Ha, MD, Joel Michalek, PhD, Richard Elledge, MD, Kevin R. Kelly, MD, PhD, Suthakar Ganapathy, PhD, Hang Su, PhD, Carol Jenkins, RN, BSN, Athanassios Argiris, MD, Ronan Swords, MD, PhD, Tony Y. Eng, MD, Anand Karnad, MD, Richard Crownover, MD, PhD, Gregory P Swanson, MD, Martin Goros, M.S., Brad H Pollock, MPH, PhD, Zhi-Min Yuan, MD, PhD

Blood (2014) 124 (21): 4809.

https://doi.org/10.1182/blood.V124.21.4809.4809

Published: 2014

Journal Articles

A Comparison of Proposed Biosimilar and Originator Filgrastim for the Prevention of Neutropenia in Patients with Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Phase III, Randomized, Double-Blind Trial (The PIONEER study)

Kimberly Blackwell, Vladimir Semiglazov, Pedro Gascon, Roumen Nakov, Stefan Kramer, Arnd Schwebig, MD, Nadia Harbeck

Blood (2014) 124 (21): 5133.

https://doi.org/10.1182/blood.V124.21.5133.5133

Published: 2014

Journal Articles

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

John Glaspy, MD, Tom Tang, MD, Dean Rutty, MSc, Xiaoqiang Yan, PhD, Igor Bondarenko, MD PhD, Dmitrii Krasnozhon, MD

Blood (2014) 124 (21): 1584.

https://doi.org/10.1182/blood.V124.21.1584.1584

Published: 2014

Journal Articles

Evidence for Mutant p53 Gain-of-Function Effects in Normal Haemopoietic Cells and Myc-Driven Lymphoma

Brandon James Aubrey, MBBS, FRACP, FRCPA, Andreas Strasser, PhD, Gemma Kelly, PhD, Lin Tai, Marco Herold, PhD

Blood (2014) 124 (21): 3589.

https://doi.org/10.1182/blood.V124.21.3589.3589

Published: 2014

Journal Articles

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Disha Malani, MSc, Astrid Murumägi, PhD, Bhagwan Yadav, MSc, Tea Pemovska, MSc, John Patrick Mpindi, MSc, Mika Kontro, MD, Tero Aittokallio, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD, Maija Wolf, PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 2163.

https://doi.org/10.1182/blood.V124.21.2163.2163

Published: 2014

Journal Articles

Risk and Consequences of Neutropenic Complications Among Patients with Metastatic Solid Tumors Receiving Myelosuppressive Chemotherapy

Derek Weycker, Ph.D., Xiaoyan Li, Ph.D., Alex Kartashov, Ph.D., Rich Barron, M.S., John Edelsberg, M.D., M.P.H., Hairong Xu, M.D., Ph.D., Vincent Girardi, M.S., Gary H. Lyman, M.D., M.P.H.

Blood (2013) 122 (21): 2962.

https://doi.org/10.1182/blood.V122.21.2962.2962

Published: 2013

Journal Articles

Use Of Pegfilgrastim Primary Prophylaxis By Chemotherapy Cycle Among Patients With Non-Hodgkin’s Lymphoma Or Breast Cancer

Wendy J Langeberg, PhD, MPH, Conchitina C Siozon, MS, PK Morrow, MD, John H Page, MD, ScD, Victoria M Chia, PhD, MPH

Blood (2013) 122 (21): 5598.

https://doi.org/10.1182/blood.V122.21.5598.5598

Published: 2013

Journal Articles

Risk of Infection Among Patients with Non-Metastatic Solid Tumors or Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy and Antimicrobial Prophylaxis in US Clinical Practice

Derek Weycker, Ph.D., David Chandler, Ph.D., Rich Barron, M.S., Hairong Xu, M.D., Ph.D., Hongsheng Wu, Ph.D., Vincent Girardi, M.S., John Edelsberg, M.D., M.P.H., Gary H. Lyman, M.D., M.P.H.

Blood (2013) 122 (21): 1730.

https://doi.org/10.1182/blood.V122.21.1730.1730

Published: 2013

Journal Articles

Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim

Andreas Lammerich, Igor Bondarenko, Udo Müller

Blood (2013) 122 (21): 4856.

https://doi.org/10.1182/blood.V122.21.4856.4856

Published: 2013

NARROW

A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)

Clinical Evidence Against the Continuum of Low-Primed Uncommitted Hematopoietic and Progenitor Cells (CLOUD-HSPC) Concept for Hematopoiesis

Clinical Evidence of Granulocyte-Monocyte Progenitor (GMP) Stem Cell Involvement in Plinabulin's Mechanism of Action (MoA) for the Prevention of Docetaxel (Doc) Chemotherapy (Chemo)-Induced Neutropenia (CIN)

Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

NEPA (netupitant + palonosetron) Administration Is Safe and Effective in cHL Patients Receiving ABVD Regimen: A Single-Center Real Life Experience

Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)

Proposed Biosimilar Pegfilgrastim (LA-EP2006) and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients with Breast Cancer: A Randomized, Double-Blind Trial. Protect 2: Pegfilgrastim Randomized Oncology (supportive care) Trial to Evaluate Comparative Treatment Results

Phase Ib Studies of Benegrastim in Chinese Women with Breast Cancer Receiving Myelotoxic Chemotherapy

Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens

The Observed and Expected Incidence of Cardiovascular (CV) Ischemic Events in Dasatinib (DAS)-Treated Patients (pts) Across a Clinical Trial Program

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

A Comparison of Proposed Biosimilar and Originator Filgrastim for the Prevention of Neutropenia in Patients with Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Phase III, Randomized, Double-Blind Trial (The PIONEER study)

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

Evidence for Mutant p53 Gain-of-Function Effects in Normal Haemopoietic Cells and Myc-Driven Lymphoma

AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines

Risk and Consequences of Neutropenic Complications Among Patients with Metastatic Solid Tumors Receiving Myelosuppressive Chemotherapy

Use Of Pegfilgrastim Primary Prophylaxis By Chemotherapy Cycle Among Patients With Non-Hodgkin’s Lymphoma Or Breast Cancer

Risk of Infection Among Patients with Non-Metastatic Solid Tumors or Non-Hodgkin’s Lymphoma Receiving Myelosuppressive Chemotherapy and Antimicrobial Prophylaxis in US Clinical Practice

Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only